<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR10">
 <label>10.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Richardson</surname>
    <given-names>PG</given-names>
   </name>
   <name>
    <surname>Moreau</surname>
    <given-names>P</given-names>
   </name>
   <name>
    <surname>Laubach</surname>
    <given-names>JP</given-names>
   </name>
   <name>
    <surname>Gupta</surname>
    <given-names>N</given-names>
   </name>
   <name>
    <surname>Hui</surname>
    <given-names>AM</given-names>
   </name>
   <name>
    <surname>Anderson</surname>
    <given-names>KC</given-names>
   </name>
   <name>
    <surname>San Miguel</surname>
    <given-names>JF</given-names>
   </name>
   <name>
    <surname>Kumar</surname>
    <given-names>S</given-names>
   </name>
  </person-group>
  <article-title>The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma</article-title>
  <source>Future Oncol</source>
  <year>2015</year>
  <volume>11</volume>
  <fpage>1153</fpage>
  <lpage>1168</lpage>
  <pub-id pub-id-type="doi">10.2217/fon.15.9</pub-id>
  <pub-id pub-id-type="pmid">25832873</pub-id>
 </element-citation>
</ref>
